G
GangaGen Biotechnologies
Creating and selling innovative products that make everyday life easier
About GangaGen Biotechnologies
GangaGen Biotechnologies Private Limited is a clinical-stage biologics company established in 2000 by Dr. Janakiraman Ramachandran, a seasoned executive with extensive experience in the biotechnology and pharmaceutical industry. The company's inception was inspired by the potential of bacteriophages as an alternative to antibiotics, a conclusion Dr. Ramachandran reached after observing the growing problem of antibiotic resistance and experiencing a personal loss due to a hospital-acquired infection. The company's name itself is a nod to the first observation of phage activity in the Ganges river. Headquartered in Bengaluru, India, GangaGen operates as a wholly owned subsidiary of Bactoclear Holdings Pte. Ltd., a Singapore-based company.
The company focuses on the discovery and development of novel protein antibiotics and phage-based therapies to combat multidrug-resistant bacterial infections. Its primary business involves research and development, with a model that includes co-development, out-licensing of its technologies, and providing customized services to other organizations. GangaGen serves the medical, veterinary, agricultural, and environmental sectors, addressing critical needs in human health and food safety. Its research has been supported by significant funding, including grants from CARB-X, a global non-profit partnership dedicated to accelerating antibacterial research.
GangaGen's product pipeline is built on its proprietary platform of developing highly specific therapeutic proteins called ectolysins and bacteriocins. A key product, P128 (also known as StaphTAME), is a recombinant protein that targets and kills *Staphylococcus aureus*, including methicillin-resistant strains (MRSA), and has advanced to human clinical trials. Another major focus is the development of Klebicins, which are protein antibiotics designed to precisely target *Klebsiella pneumoniae*, a pathogen of high concern due to its resistance to multiple antibiotics. Beyond human therapeutics, GangaGen has developed a phage cocktail to control *Salmonella* infections in the poultry industry and has explored applications for tackling bacteria in aquaculture and industrial settings.
Source: Dealroom company dataNews
Open roles
GangaGen Biotechnologies in the Bengaluru ecosystem
The GangaGen Biotechnologies office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
ATEL Ventures
CARB-X
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about GangaGen Biotechnologies on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See GangaGen Biotechnologies on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

